FDA Will Review Safety of Testosterone Therapy
Agency pointed to recent studies citing possible heightened heart risk tied to the treatments
WebMD News Archive
By Kathleen Doheny
SUNDAY, Feb. 2, 2014 (HealthDay News) -- Spurred by a recent report that popular testosterone treatments might raise men's heart risk, the U.S. Food and Drug Administration says it now plans a review of the therapies' safety.
"FDA is investigating the risk of stroke, heart attack and death in men taking FDA-approved testosterone products," the agency said in a statement released late Friday.
"We have been monitoring this risk and decided to reassess this safety issue based on the recent publication of two separate studies that each suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy," the agency added.
Testosterone therapy has been widely advertised as a way to help aging men improve low sex drive and reclaim diminished energy.
However, in a study published Wednesday in the journal PLoS One, an increased risk of heart attack was found in men younger than 65 with a history of heart disease, and in older men even if they didn't have a history of the disease.
In both groups, heart attack risk doubled in the 90 days after the men began testosterone therapy, said researcher William Finkle, CEO of Consolidated Research, in Los Angeles.
"It was more or less the same increase in risk," Finkle said.
In its Friday statement, the FDA said that, as of now, the agency "has not concluded that FDA-approved testosterone treatment increases the risk of stroke, heart attack or death. Patients should not stop taking prescribed testosterone products without first discussing any questions or concerns with their health care professionals."
But the FDA also told doctors that they "should consider whether the benefits of FDA-approved testosterone treatment is likely to exceed the potential risks of treatment."
Testosterone therapy typically is given in gel, patch or injection form, and is widely promoted in television advertisements about "low T." Although the treatment risk to men over 65 has been documented in previous research, Finkle said, the new study is believed to be the first to look at men under 65.